Literature DB >> 19152733

Psychiatric symptoms related to the use of lamotrigine: a review of the literature.

Vincenzo Villari1, Paola Rocca, Tiziana Frieri, Filippo Bogetto.   

Abstract

Lamotrigine is an established anticonvulsant agent and also an effective maintenance therapy for bipolar disorder. In Italy it is approved for the treatment of epilepsy with partial seizures, partial seizures with secondary generalization and generalized seizures, both in monotherapy and as an add-on therapy in patients with refractory epilepsy; it is also approved for the prevention of depressive episodes in patients with bipolar disorder with a predominant depressive component. Lamotrigine is generally well tolerated; however, some psychiatric problems have been reported in patients using the drug to treat mental disorders (mainly bipolar) or epilepsy. The clinical features of these psychiatric side effects are: affective switches, full acute psychotic episodes, and hallucinations. In conclusion, lamotrigine is an effective drug, very useful in the therapy of epilepsy and mood disorders, but clinicians have to be aware of the risk that it can induce psychiatric symptoms or acute episodes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19152733

Source DB:  PubMed          Journal:  Funct Neurol        ISSN: 0393-5264


  3 in total

1.  Vulnerability of an epileptic case to psychosis: sodium valproate with lamotrigine, forced normalization, postictal psychosis or all?

Authors:  A B Turan; M Seferoglu; O Taskapilioglu; I Bora
Journal:  Neurol Sci       Date:  2011-12-01       Impact factor: 3.307

2.  Compulsive versifying after treatment of transient epileptic amnesia.

Authors:  Ione O C Woollacott; Phillip D Fletcher; Luke A Massey; Amirtha Pasupathy; Martin N Rossor; Diana Caine; Jonathan D Rohrer; Jason D Warren
Journal:  Neurocase       Date:  2014-08-26       Impact factor: 0.881

3.  Effect of lamotrigine in the treatment of bipolar depression with psychotic features: a case report.

Authors:  Tomoko Kajiya; Hiroko Sugawara; Yusuke Kajio; Satoru Morieda; Hibiki Tanaka; Tadashi Jono; Noboru Fujise; Mamoru Hashimoto
Journal:  Ann Gen Psychiatry       Date:  2017-08-09       Impact factor: 3.455

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.